CDCA3抗体;CDCA3 Antibody—艾普蒂

CDCA3 (Cell Division Cycle Associated 3) is a protein-coding gene implicated in regulating cell cycle progression, particularly during the G1/S transition and mitotic exit. It functions as a substrate-recognition component of the E3 ubiquitin ligase complex, targeting specific proteins for proteasomal degradation via the ubiquitin-proteasome system. CDCA3 interacts with the anaphase-promoting complex/cyclosome (APC/C), facilitating the degradation of cell cycle regulators like cyclin B1 and securin to ensure proper mitotic exit and genome stability. Dysregulation of CDCA3 has been linked to aberrant cell proliferation, chromosomal instability, and cancer progression. CDCA3 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess CDCA3 levels in tissues or cell lines. Research highlights its overexpression in certain cancers (e.g., hepatocellular carcinoma, lung adenocarcinoma), where it correlates with poor prognosis, suggesting its potential as a diagnostic or prognostic biomarker. Additionally, CDCA3 is being explored as a therapeutic target, particularly in cancers with cell cycle dysregulation. Studies also investigate its role in DNA damage response and chemotherapy resistance, further underscoring its biological and clinical relevance.